PATH (polyneuropathy and treatment with Hizentra ®: a randomized, controlled trial of Hizentra ®, a 20% immunoglobulin preparation for subcutaneous administration, in patients with chronic inflammatory demyelinating polyradiculoneuropathy
F1000Research（2012）
关键词
health,biology,publishing,microbiology,genetics,cell biology,ecology,oncology,anaesthesiology,medicine,plant biology,neuroscience,physiology
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要